Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elismetrep compared with a placebo for treating acute migraine attacks. This randomized, double-blind, phase III trial is conducted at multiple outpatient centers and sponsored by TriGemX Bio, Inc. The study focuses on adults aged 18 to 75 years who experience moderate to severe migraines lasting 4 to 72 hours, with a history of at least 2 but no more than 10 migraine attacks per month. Participants are randomly assigned to one of three groups elismetrep 10 mg, elismetrep 20 mg, or placebo. All treatments are taken orally during a migraine attack. The trial uses a parallel study design and is triple-blinded to ensure unbiased results. The main study period extends until February 2027, with participants monitored for responses two hours after dosing. During the study, participants will complete questionnaires and use an electronic diary on their smartphones to track migraine symptoms and treatment effects. Researchers will assess outcomes such as pain freedom, relief from bothersome symptoms, and functional disability at two hours post-dose. Additional evaluations include monitoring for adverse events up to eight days after dosing. Participants must follow the study schedule and complete all trial procedures to help assess elismetreps potential as an acute migraine treatment.
Actively Recruiting
Researchers are evaluating AXS-14 esreboxetine for managing fibromyalgia in a Phase 3, double-blind, placebo-controlled, randomized withdrawal study. The study aims to assess the efficacy and safety of AXS-14 for people diagnosed with fibromyalgia based on the 2016 ACR diagnostic criteria. The trial includes a multi-center design with two main periods. First, participants receive open-label AXS-14 tablets once daily for up to 12 weeks. Those who respond to treatment are then randomized to either continue AXS-14 or switch to placebo for an additional 12 weeks or until loss of therapeutic response occurs. Participants will be involved for up to 24 weeks in total. During this time, they will take study tablets daily and undergo assessments to monitor their response and safety. The primary outcome measured is the time from randomization to loss of therapeutic response over 12 weeks. Safety and efficacy are closely monitored throughout the study.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two different oral doses of vapendavir compared to a placebo to find the right dose for reducing the severity and duration of respiratory symptoms caused by rhinovirus infections in people with chronic obstructive pulmonary disease COPD. This phase 2 clinical trial involves adult participants aged 40 to 85 years who have a confirmed COPD diagnosis and recent history of acute exacerbations. Participants will be randomly assigned to one of three groups one receiving 1000 mg of vapendavir, another receiving 500 mg of vapendavir, and the third receiving a placebo. The first dose is taken at the study site with food, followed by doses at home once daily with food for a total of seven doses. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will complete daily evaluations of respiratory symptoms and severity using patient-reported outcome tools, including the Evaluating Respiratory Symptoms E-RS and Patient Global Impression of Severity PGIS scales. Lung function tests and oscillometry measurements will be conducted at multiple time points up to 42 days. The study aims to measure changes in respiratory symptoms and lung function to assess treatment impact and safety. Participation lasts for up to 12 weeks including baseline, treatment, and follow-up periods.